Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical ...
MetaVia Inc. (NASDAQ: MTVA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company’s stated mission is to transform cardiometabolic diseases by discovering and developing therapies that target key metabolic pathways. Its pipeline is built around multiple drug candidates at different stages, spanning early development through Phase 2a. A ...MetaVia Inc. (NASDAQ: MTVA) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company’s stated mission is to transform cardiometabolic diseases by discovering and developing therapies that target key metabolic pathways. Its pipeline is built around multiple drug candidates at different stages, spanning early development through Phase 2a.
A central program is DA-1241, a unique G-Protein-Coupled Receptor 119 agonist. According to the provided company overview, DA-1241 has completed Phase 1 trials for type 2 diabetes mellitus (T2DM) and is advancing in Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). The company positions this candidate as potentially useful both as a standalone therapy and as part of combination regimens—an approach commonly used in metabolic and liver disease indications to improve efficacy while tailoring patient response.
MetaVia’s other major development asset is DA-1726, described as an oxyntomodulin analogue and a dual GLP-1/glucagon receptor agonist. DA-1726 is in preclinical development with a focus on obesity, reflecting the company’s emphasis on addressing disorders with significant unmet medical need and that often benefit from receptor-pathway modulation.
Beyond these primary programs, MetaVia also references a broader pipeline including ANA001 (an oral niclosamide formulation intended for moderate COVID-19 patients), NB-01 (for painful diabetic neuropathy), NB-02 (for cognitive impairment), and Gemcabene (for dyslipidemia). The inclusion of multiple therapeutic areas underscores that the company operates as a platform-style developer, pursuing several internal candidates while also leveraging strategic relationships.
In terms of partnerships and business model, MetaVia has highlighted a licensing agreement with Pfizer Inc. related to Gemcabene across research, development, manufacturing, and commercialization. The company also cites joint research collaborations (e.g., involving Dong-A ST and ImmunoForge) supporting the advancement of DA-1726. These collaborations can reduce development risk and help fund or accelerate specific programs—an important consideration for small, clinical-stage biopharma companies.
From a financial and operational perspective, the provided data suggests MetaVia is a very small organization (employee count referenced in the single digits to low tens; overall size class 0–100). As a clinical-stage biotech, it typically requires substantial cash to advance trials, scale regulatory work, and support manufacturing readiness, and therefore may not yet have meaningful revenues. The company’s valuation and profitability metrics in the provided dataset appear consistent with early-stage biotech economics (i.e., limited or negative earnings), while balance sheet measures indicate it maintains liquidity.
Key leadership includes CEO and President Hyung Heon Kim (in role since 2023 per the provided information). As MetaVia is still building its clinical programs, future “wishes” for the business likely center on successful trial readouts for DA-1241 and DA-1726, advancing additional assets through the clinic, expanding or optimizing partnerships, and continuing to strengthen its pipeline while maintaining sufficient funding to support trial milestones.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-13.0M
+53.0%
-39.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-15.7M
+36.5%
+11.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
3.9%
+129.6%
+21.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.93x
-0.9%
-24.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
